Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report

RATIONALE: Sildenafil, a phosphodiesterase-5-inhibitor and Bosentan, an endothelin-1-receptor antagonist combined therapy could have beneficial effect in systemic sclerosis (SSc) patients with peripheral artery disease. PATIENT CONCERNS: We report a case of a 48-year-old Black woman, who developed s...

Descripción completa

Detalles Bibliográficos
Autores principales: Omarjee, Loukman, Fontaine, Cedric, Mahe, Guillaume, Jaquinandi, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484185/
https://www.ncbi.nlm.nih.gov/pubmed/28640077
http://dx.doi.org/10.1097/MD.0000000000006988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484185/
https://www.ncbi.nlm.nih.gov/pubmed/28640077
http://dx.doi.org/10.1097/MD.0000000000006988

Ejemplares similares